Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Document Viewer

Share this page:

Title

Subject

Description

EUA: For emergency use by healthcare providers for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Creator

U.S. Food and Drug Administration

Date Last Updated (Year-Month-Day)

2020-11-19

Citation

Download Heathcare Providers Fact Sheet directly: https://www.fda.gov/media/143823/download

Download Patients, Parents, and Caregivers Fact Sheet directly: https://www.fda.gov/media/143824/download

Download the Frequently Asked Questions on the Emergency Use Authorization for Olumiant (baricitinib) in Combination with Veklury (remdesivir) for Treatment of Mild to Moderate COVID-19

URL

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

Click for External Resource

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

*This link may link to a hosted zip file or an external resource. Zip files will download automatically. Other links will open in a new window.

Files for download

Item Type:

Guide

Collection

Implement

Citation for this page

U.S. Food and Drug Administration, “Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB,” NETEC Resource Library, accessed January 19, 2021, https://repository.netecweb.org/items/show/1406.

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.